Green leaf group deeply implements four strategies to rush to the top 50 pharmaceutical companies in the world

[China Pharmaceutical network enterprise news] Based on the research and development of innovative pharmaceutical preparations and antibody drugs such as microspheres and liposomes, green leaf life science group will accelerate the research on nano crystalline long-term preparations, transdermal patches, intelligent preparations and new target antibody drugs, continue to expand new business areas, and promote the continuous improvement of new drug research and development technology in China LVYE Life Science Group carefully studied and implemented the spirit of the working conference on building a strong manufacturing industry in the city, thoroughly implemented the "four strategies" of investment and financing M & A, R & D innovation, advanced manufacturing system construction, marketing and brand, and strive to achieve the strategic goal of entering the top 30 pharmaceutical industry in China and the top 50 pharmaceutical enterprises in the world In recent years, LVYE Life Sciences Group has successfully acquired foreign pharmaceutical companies such as Switzerland and Australia, greatly improving the research and development and production level of new preparations, and enhancing its comprehensive strength in the field of life sciences At the same time of speeding up the pace of international M & A, LVYE pharmaceutical continues to open up the international market At present, five products have been registered in the United States, among which risperidone sustained-release microspheres for injection are about to submit new drug applications in the United States Next, green leaf will focus on promoting the listing of these five products in the United States, and strive to achieve the domestic listing of 3-4 innovative products with independent intellectual property rights and the listing of 2-3 new drugs in the United States by 2020, so as to achieve the zero breakthrough in the listing of new drugs with independent intellectual property rights in developed countries Liu Dianbo, chairman of the board of directors of green leaf life science group, said: "the whole green leaf R & D system is a very international system, which is in line with the global new technology In the next three to five years, more than a dozen products of our group will be launched into the global market, which will have a qualitative change in the development of green leaves " LVYE life science group will also speed up the introduction of global medical technology and quality management system; strive to build four medical centers in North China, East China, South China and West China; actively develop diagnostic business, research and develop molecular diagnostic technology and products; We will firmly promote the construction of Boston R & D center, optimize and integrate global R & D resources, and strive to achieve the goal of "becoming a respected global enterprise in the field of health" Based on the research and development of innovative pharmaceutical preparations and antibody drugs such as microspheres and liposomes, LVYE life science group will accelerate the research on nano crystalline long-term preparations, transdermal patches, intelligent preparations and new target antibody drugs, continue to expand new business areas, and promote the continuous improvement of new drug research and development technology in China "We have built a production base of nearly 200000 square meters in the industrial park of the high tech Zone to supply the world," Liu said By 2020, our pharmaceutical sector will exceed $2 billion By 2025, we will be over 40 billion yuan We hope that through our efforts, we will continue to innovate some new drugs that meet the needs of the international market and clinical needs, contribute to people's health, and make our due contribution to the development of Yantai medical and health industry " Original title: green leaf group "four strategies" to build a global pharmaceutical enterprise